Business
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
CRANBURY, N.J., April 28, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":465,"url":"https://media.zenfs.com/en/business-wire.com/b10474c0c383a0ba2cbd6fb356fe29a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BK4aJm9YvSTb.YgmajqzDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3Mg--/https://media.zenfs.com/en/business-wire.com/b10474c0c383a0ba2cbd6fb356fe29a5","width":960,"height":372},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zDUbppB.8DxTyISMDrKXsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05MzA-/https://media.zenfs.com/en/business-wire.com/b10474c0c383a0ba2cbd6fb356fe29a5","width":1200,"height":465}},"lazy":false},{"type":"text","content":"PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"Cash runway extended into the second quarter of 2028","length":52,"tagName":"p","attribs":{}},{"type":"text","content":"CRANBURY, N.J., April 28, 2026--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).","length":377,"tagName":"p"},{"type":"text","content":"Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded following the U.S. Food and Drug Administration (FDA) accelerated approval of KRESLADI™ (marnetegragene autotemcel). The transaction reflects the continued strategic value of PRVs, as well as Rocket’s disciplined approach to capital formation and allocation in support of its prioritized cardiovascular gene therapy programs.","length":426,"tagName":"p"},{"type":"text","content":""The monetization of our PRV, following the FDA approval of KRESLADI, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of 2028," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. "This strengthens our ability to advance key clinical milestones across our cardiovascular gene therapy pipeline, with all programs on track."","length":410,"tagName":"p"},{"type...